Biostatistics and Tumor Marker Studies in Breast Cancer: Design,Analysis and Interpretation Issues

Bast R.C. Jr. , Ravdin P. , Hayes D.F. . 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865–78.

Goldhirsch A. , Glick J.H. , Gelber R.D. , Coates A.S. , Senn H-J . Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Clin Oncol 2001; 19: 3817–27.

Simon R. , Altman D.G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994; 69: 979–85.

Altman D.G. , Lyman G.H. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998; 52: 289–303.

Pajak T.F. , Clark G.M. , Sargent D.J. , McShane L.M. , Hammond M.E. Statistical issues in tumor marker studies. Arch Pathol Lab Med 2000; 124: 1011–5.

Clark G.M. Interpreting and integrating risk factors for patients with primary breast cancer. J Natl Cancer Inst Monogr 2001; 17–21.

Paradiso A. , Volpe S. , Iacobacci A. . Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT). Int J Biol Markers 2002; 17: 201–14.

Biganzoli E. , Boracchi P. , Daidone M.G. , Gion M. , Marubini E. Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers. Int J Biol Markers 1998; 13: 107–23.

Cox D. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187–200.

Boracchi P. , Biganzoli E. , Marubini E. Joint modelling of cause specific hazard functions with cubic splines: an application to a large series of breast cancer patients. Comp Statistics Data Analysis 2002 (in press).

Biganzoli E. , Boracchi P. , Marubini E. A general framework for neural network models on censored survival data. Neural Networks 2002; 15: 49–58.

Hayes D.F. , Trock B. , Harris A.L. Assessing the clinical impact of prognostic factors: when is “statistically significant” clinically useful? Breast Cancer Res Treat 1998; 52: 305–19.

Boracchi P. , Biganzoli E. Markers of prognosis and response to treatment: ready for clinical use in oncology? A biostatistician's viewpoint. Int J Biol Markers 2003 (in press).

Menard S. , Valagussa P. , Pilotti S. . Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001; 19: 329–35.

Yamauchi H. , Stearns V. , Hayes D.F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334–56.

Allred D.C. , Clark G.M. , Tandon A.K. . HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599–605.

Miles D.W. , Harris W.H. , Gillett C.E. , Smith P. , Barnes D.M. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 1999; 84: 354–9.

Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 1981; 68: 316–9.

Marubini E. Evidenza scientifica e statistica in la salute tra informazione e prova scientifica. In: Gallo C. , Signoriello G. , eds. SISMEC Conference Proceedings, 2001; 11–8.

Gusterson B.A. , Gelber R.D. , Goldhirsch A. . Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049–56.

Fitzgibbons P.L. , Page D.L. , Weaver D. . Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966–78.